Entrada Therapeutics (TRDA) Other Non-Current Assets (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Other Non-Current Assets of $3.3 million for Q1 2026, up 1277.41% year-over-year from $239000.0 in Q1 2025, and up 4602.86% quarter-over-quarter from $70000.0 in Q4 2025.
Entrada Therapeutics (TRDA) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $3.3 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 1277.41% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (up 1277.41% YoY), while the FY2025 annual figure was $70000.0, down 75.35% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $3.3 million, up from $70000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $13.8 million in Q1 2023, with the low at $70000.0 in Q4 2025.
- The 5-year median for Other Non-Current Assets is $3.3 million (2026), against an average of $2.9 million.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets plunged 95.87% in 2025, then soared 1277.41% in 2026.
- Entrada Therapeutics' Other Non-Current Assets stood at $4.0 million in 2022, then declined by 29.37% to $2.8 million in 2023, then plunged by 89.82% to $284000.0 in 2024, then sank by 75.35% to $70000.0 in 2025, then soared by 4602.86% to $3.3 million in 2026.
- Business Quant data shows TRDA's Other Non-Current Assets at $3.3 million in Q1 2026, $70000.0 in Q4 2025, and $163000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 3.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.29 Mn |
| Mar 31, 2026 | 3.29 Mn |
| Dec 31, 2025 | 70,000.00 |
| Sep 30, 2025 | 163,000.00 |
| Jun 30, 2025 | 199,000.00 |
| Mar 31, 2025 | 239,000.00 |
| Dec 31, 2024 | 284,000.00 |
| Sep 30, 2024 | 3.95 Mn |
| Jun 30, 2024 | 747,000.00 |
| Mar 31, 2024 | 3.95 Mn |
| Dec 31, 2023 | 2.79 Mn |
| Sep 30, 2023 | 3.95 Mn |
| Jun 30, 2023 | 538,000.00 |
| Mar 31, 2023 | 13.84 Mn |
| Dec 31, 2022 | 3.95 Mn |
| Sep 30, 2022 | 3.95 Mn |
| Jun 30, 2022 | 3.95 Mn |
| Mar 31, 2022 | 3.95 Mn |
| Dec 31, 2021 | 872,000.00 |
| Sep 30, 2021 | 2.97 Mn |